Short summary

Treatment with glucocorticoids (GCs) is known to cause bone loss. However, the skeletal response varies a lot between individuals. In this study we will include 36 study participants, that will be randomized to receive either GC treatment or placebo. They will have blood samples and tissue samples taken during the study. The aim of this study is to find a biomarker, that can identify individuals at risk of glucocorticoid-induced bone disease, and to understand the mechanism behind this.

Rationale

Treatment with glucocorticoids (GCs) is used for a variety of inflammatory conditions. Long-term treatment with GCs may cause bone loss due to inhibition of bone formation and continuation of bone resorption. However, the skeletal response to GC treatment varies significantly between individuals. While some experience extensive bone loss during GC treatment, bone mass remains intact in other individuals. The aim of this study is to find a biomarker, that can identify individuals at risk of glucocorticoid-induced bone disease, and to understand the mechanism behind this.

Description of the cohort

We will include 36 healthy volunteers (aged 18-50 years). The study participants will be randomized to receive either 7 days of treatment with the glucocorticoid prednisolone 25 mg/day or placebo (2:1 randomization ratio).

Data and biological material

Blood samples, bone marrow samples, bone tissue samples and adipose tissue samples.

Collaborating researchers and departments

Department of Endocrinology, Esbjerg and Grindsted Hospital, University Hospital of Southern Denmark

• Claus Bogh Juhl